Hydroxychloroquine is protective to the heart, not harmful: a systematic review

C. C. Prodromos, T. Rumschlag and T. Perchyk
Foundation for Orthopaedics and Regenerative Medicine, 1714 Milwaukee Ave, Glenview, IL, 60025, USA

Abstract

Hydroxychloroquine (HCQ) has been shown to be at least somewhat effective in treating patients with coronavirus disease 2019 (COVID-19). Recently the US Food and Drug Administration and Centers for Disease Control and Prevention warnings of fatal cardiac toxicity from torsades de pointes (TDP) arrhythmia from HCQ receipt have been made, notwithstanding the long safe provision of HCQ to treat lupus and rheumatoid arthritis. This has resulted in restricted access of HCQ for COVID-19 treatment. We hypothesized that HCQ and azithromycin have not been reported to cause significant acute cardiac arrhythmic mortality. We performed a literature search for the effects of HCQ and azithromycin on the heart. No TDP or related deaths were found to have been reported as a result of HCQ and azithromycin receipt in the peer-reviewed literature. On the contrary, HCQ and azithromycin were both found to substantially reduce cardiac mortality and also decrease thrombosis, arrhythmia and cholesterol in treated patients in recent peer-reviewed studies and meeting presentations. HCQ and azithromycin do not cause TDP cardiac mortality; rather, HCQ decreases cardiac events. HCQ should not be restricted in COVID-19 patients out of fear of cardiac mortality.

Keywords: Azithromycin, COVID-19, hydroxychloroquine, SARS-CoV-2

Introduction

Several clinical studies, which by now have assessed thousands of patients [1–4], have shown apparent substantial clinical benefit from the receipt of hydroxychloroquine (HCQ) in coronavirus disease 2019 (COVID-19) patients and have not reported adverse cardiac events. A number of meta-analyses [5–7] have also shown overall good results, although with limited quality studies. Provision of HCQ by physicians who were so inclined is therefore warranted to treat COVID-19 unless there are significant clinical risks to offset the apparent benefits.

However, recently numerous warnings have been issued from the US Food and Drug Administration (FDA) [8], the Centers for Disease Control and Prevention [9], the American Heart Association [10] and elsewhere about potential fatal cardiac toxicity from torsades de pointes (TDP) or other ventricular arrhythmias from HCQ receipt. These warnings state that such fatalities could occur as a result of the increase in QTc that is sometimes seen with the receipt of HCQ as well as with azithromycin, which is often used in combination with HCQ. The FDA warning, released on 15 June 2020 along with a revocation of its prior emergency use authorization, states, ‘Additionally, in light of ongoing serious cardiac adverse events and other potential serious side effects, the known and potential benefits of chloroquine and HCQ no longer outweigh the known and potential risks for the authorized use’ [11]. However, this warning does not reference any specific study or note whether any related deaths had occurred.

These warnings seemed odd to us because HCQ has been provided to millions of patients with lupus or rheumatoid arthritis (RA) for more than 50 years with a general reputation for safety [12]. Practicing rheumatologists generally prescribe it without ordering a baseline electrocardiogram (EKG) unless the patient has a history of cardiac disease. The 2019 HCQ
recommendations for the European League Against Rheumatology (EULAR) only mention screening for retinal toxicity in patients receiving HCQ for extended periods of time [12]. Furthermore, azithromycin is also regularly prescribed without a baseline EKG, and is not generally thought to be cardiotoxic to patients with an otherwise normal heart.

These warnings have had the effect of restricting HCQ provision in the hospital setting in some locales. This may not be consistent with good patient care because HCQ is known to be best applied earlier in the patient course, before hospitalization. It has also resulted in some pharmacists or entire pharmacy boards [13] refusing to fill HCQ prescriptions for COVID-19, thus restricting access to a potentially beneficial drug.

Thus, it would be of great benefit to know whether there is in fact significant cardiac risk from the receipt of HCQ. We hypothesized that the scientific literature would not show clinical evidence of increased cardiac mortality from HCQ or HCQ plus azithromycin from TDP. That is, we thought that the reported putative potential cardiac risk [9] of cardiac mortality would not be accompanied by reports of actual TDP or other QTc-related cardiac mortality.

Materials and methods

We limited this study to HCQ and not chloroquine (CQ) because CQ is more toxic than HCQ, such that we do not believe CQ has a place in the treatment of COVID-19, particularly given the wide availability and low cost of HCQ.

We also excluded reports of HCQ cardiomyopathy. This is a rare condition that is only seen after many years (usually decades) of receipt of HCQ, and thus it is not relevant to the brief periods of time that HCQ is used to treat COVID-19. This cardiomyopathic damage is also not what is referenced by agencies that warn of HCQ cardiotoxicity, instead referring to cardiomyopathic damage is also not what is referenced by agencies that warn of HCQ cardiotoxicity, instead referring to a baseline EKG, and is not generally thought to be cardiotoxic to patients with an otherwise normal heart.

Overall, our literature search found that except for a few case reports of nonfatal adverse events, HCQ is actually consistently associated with a decreased incidence of cardiac adverse events and no cardiac mortality from TDP. Table 1 lists the relevant studies.

Nonfatal cardiac adverse event case reports

We found three case reports of patients with increased QTc or other conduction block arrhythmia in patients with lupus [16–18] and one in a patient with COVID-19 [19]. However, in all cases, the patients were successfully treated without any deaths occurring.

Nonfatal cardiac adverse event clinical series

We found one case series describing 251 COVID-19 patients treated with HCQ and azithromycin [36]. A total of 23% developed extreme QTc prolongation. However, HCQ was discontinued in patients with QTc prolongation, and no deaths occurred.

Cardiac mortality from HCQ-induced TDP or other arrhythmia

We found no reports of cardiac death from TDP or other arrhythmia due to receipt of HCQ.

Decreased incidence of cardiac events with HCQ

Eight articles showed a decreased incidence of cardiovascular disease (CVD) in patients receiving HCQ. Hung et al. [23] in 2018 found a decrease in risk of coronary artery disease in RA patients receiving HCQ. Liu et al. [37] found this protective effect of HCQ on coronary artery disease was applicable across a range of ages, the two genders and multiple comorbidities as well as a lower risk of CVD in patients with rheumatic diseases treated with HCQ or CQ. Rempenault et al. [38] in 2018 found that CQ and HCQ lowered CVD in rheumatic disease. Mathieu et al. [39] also in 2018 found that RA patients receiving HCQ had an improved cardiovascular risk profile compared to other RA patients.

Sharma et al. [30] in 2016 found that HCQ receipt was associated with a 72% decrease in the risk of incident CVD in RA patients. Van Halm et al. [29] in 2006 found that HCQ reduced cardiac events in RA patients. Yang et al. [31] in 2019 found a decreased risk for coronary artery disease in patients...
| Study                     | Study type        | No. of patients | HCQ dosage | HCQ duration | Associated medications | Comorbidities of patients and cardiac background | Study findings                      |
|--------------------------|-------------------|-----------------|-------------|--------------|------------------------|-------------------------------------------------|-------------------------------------|
| Morgan 2013 [16]         | Case report       | 1               | 200 mg twice daily | 3 years     | NA                     | 41-year-old woman with CHF and left ventricular dysfunction and with SLE and hypertension; received renal transplant 3 years before | QTc prolongation                     |
| O’Laughlin 2016 [17]     | Case report       | 1               | 200 mg daily   | 2 years     | NA                     | 50-year-old woman with history of SLE, ESRD treated with dialysis and AFB receiving anticoagulation therapy | QTc prolongation                     |
| Chen 2006 [18]           | Case report       | 1               | 200 mg daily   | 1 year      | 15 mg prednisolone daily, 200 mg theophylline daily | 67-year-old woman with history of SLE, liver cirrhosis and portal vein thrombosis, asthma and old myocardial infarct with ventricular septal defect | Prolonged QTc leading to TDP         |
| Asli 2020 [19]           | Case report       | 1               | 400 mg stat dose, then 200 mg twice daily | 3 days | Initially amoxicillin/clavulanic acid; switched to meropenem 1000 mg three times daily | 60-year-old woman with history of hypertension hypertesia and overweight | Right bundle branch block and prolonged QTc |
| Erkan 2002 [20]          | Cross-sectional study | 133 patients with antiphospholipid syndrome | NA | NA | NA | All patients with history of antiphospholipid syndrome | Found lower rate of thrombosis in aPL-positive patients receiving therapy with either aspirin or HCQ |
| Izmirly 2012 [21]        | Historical cohort study | 40 neonates whose mothers received HCQ before delivery | At least 200 mg daily | At least before 10 weeks’ gestation | NA | Neonates whose mothers previously gave birth to a child with cardiac neonatal lupus or whose mother had anti-SSA/Ro and/or SSB/La antibodies | Infants with mothers receiving HCQ had 64% lower chance of developing cardiac neonatal lupus |
| Petri 1994 [22]          | Longitudinal cohort study | 264 total patients, 125 patients receiving HCQ | NA | NA | 80% of all patients in study receiving prednisone | All patients with SLE | HCQ receipt was associated with lower serum cholesterol levels Showed decreased risk of coronary artery disease in RA patients receiving HCQ. HCQ blood levels inversely associated with risk of any thrombotic event Patients receiving either HCQ or CQ were less likely to experience a thrombotic event. Diastolic blood pressure, serum LDL and triglyceride levels were all lower in patients currently receiving HCQ or CQ |
| Hung [23]                | Population-based retrospective cohort study | 173 in HCQ group | NA | >180 days | NA | Rheumatoid arthritis patients |                                             |
| Konig 2019 [24]          | Prospective cohort study | 812 patients | NA | NA | NA | All patients with SLE |                                             |
| Ruiz-Irastorza 2006 [25] | Prospective cohort study | 104 patients receiving HCQ | NA | average 52 months | NA | 232 patients with SLE |                                             |
| Rio 2009 [26]            | Prospective cohort study | 169 total patients, 42 currently receiving either HCQ or CQ | NA | NA | 71% of all patients in study receiving methotrexate | All patients with RA |                                             |
| Million 2020 [2]         | Prospective cohort study | 1061 patients | 200 mg HCQ three times daily | 10 days | 500 mg azithromycin day |                                             | Continued}

© 2020 The Author. Published by Elsevier Ltd. NMNI, 37, 100747

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
TABLE 1. Continued

| Study               | Study type       | No. of patients | HCQ dosage | HCQ duration | Associated medications | Comorbidities of patients and cardiac background | Study findings |
|---------------------|------------------|-----------------|------------|--------------|-------------------------|-----------------------------------------------|---------------|
| Bun 2020 [27]       | Prospective cohort study | 71 patients receiving HCQ | 200 mg three times daily | 10 days | Azithromycin 500 mg daily | Patients with PCR-confirmed COVID-19 of >60 ms from baseline, although no patient exceeded 500 ms QTc; no incidents of TDP reported Significant QTc prolongation leading to therapy withdrawal in 2 patients; no incidences of drug-induced life-threatening arrhythmias or death observed |               |
| Saleh 2020 [28]     | Prospective observational study | 201 total patients, 191 receiving HCQ | 400 mg twice on day 1, then 200 mg twice daily for days 2–5 | 5 days | All patients also receiving azithromycin 500 mg daily for 5 days | Patients receiving azithromycin had greater rates of QTc prolongation; only discontinued in 3.5% of patients; no instances of TDP RA patients receiving DMARDs (including HCQ) reduced risk for CVD Rheumatoid arthritis patients receiving HCQ showed 72% reduction in all CVD events Risk for coronary artery disease decreased in patients with high cumulative doses of HCQ (>100 @ 267) Patients receiving HCQ had lower risk of arterial and venous CVD events Lower risk of atrial fibrillation in patients receiving HCQ 7 patients developed prolonged QTc of over 500 ms; 3 patients had increase in QTc of 50 ms or more; 1 case of TDP reported 12 patients with QTc over 500 ms; average patient increased QTc by 7.6 ms while receiving treatment; average on-treatment QTc was 430.9 ms QTc >500 ms in 23% of patients; one patient developed polymorphic ventricular tachycardia (suspected to be TDP) |               |
| Van Hallm 2006 [29] | Retrospective case control study | 613 total patients receiving DMARDs, 244 of these receiving HCQ | NA | NA | NA | All patients with history of CVD excluded from study |               |
| Sharma 2016 [30]    | Retrospective cohort study | 547 patients receiving HCQ | Variable; grouped as <105, 105–318 and > 318 | NA | NA | Patients with history of CVD excluded from study |               |
| Yang 2019 [31]      | Retrospective cohort study | 795 patients receiving HCQ | NA | Variable; grouped as <105, 105–318 and > 318 | NA | Patients with history of CVD excluded from study |               |
| Shapiro 2017 [32]   | Retrospective cohort study | 241 patients receiving HCQ | Either 400 mg daily or 200 mg daily | NA | Most patients also receiving prednisone or methotrexate | Patients receiving HCQ had lower risk of arterial and venous CVD events Lower risk of atrial fibrillation in patients receiving HCQ 7 patients developed prolonged QTc of over 500 ms; 3 patients had increase in QTc of 50 ms or more; 1 case of TDP reported 12 patients with QTc over 500 ms; average patient increased QTc by 7.6 ms while receiving treatment; average on-treatment QTc was 430.9 ms QTc >500 ms in 23% of patients; one patient developed polymorphic ventricular tachycardia (suspected to be TDP) |               |
| Gupta 2018 [33]     | Retrospective cohort study | 754 patients receiving HCQ | NA | NA | NA | All patients with rheumatic disease |               |
| Mercuro 2020 [34]   | Retrospective cohort study | 90 | 400 mg twice on day 1, then 200 mg twice daily for days 2–5 | 5 days | 53 patients also receiving azithromycin | Patients with PCR-confirmed COVID-19; most patients had at least one cardiovascular comorbidity 7 patients developed prolonged QTc of over 500 ms; 3 patients had increase in QTc of 50 ms or more; 1 case of TDP reported 12 patients with QTc over 500 ms; average patient increased QTc by 7.6 ms while receiving treatment; average on-treatment QTc was 430.9 ms QTc >500 ms in 23% of patients; one patient developed polymorphic ventricular tachycardia (suspected to be TDP) |               |
| Hooks 2020 [35]     | Retrospective cohort study | 819 patients receiving HCQ | Median dose 400 mg daily | Median duration 1006 days | NA | All patients with rheumatic disease |               |
| Chorin 2020 [36]    | Retrospective study | 251 | Loading dose of 400 mg twice for 1 day, then 200 mg twice daily | 5 days | Azithromycin 500 mg daily | Patients with PCR-confirmed COVID-19; most patients had at least one cardiovascular comorbidity 7 patients developed prolonged QTc of over 500 ms; 3 patients had increase in QTc of 50 ms or more; 1 case of TDP reported 12 patients with QTc over 500 ms; average patient increased QTc by 7.6 ms while receiving treatment; average on-treatment QTc was 430.9 ms QTc >500 ms in 23% of patients; one patient developed polymorphic ventricular tachycardia (suspected to be TDP) |               |
| Liu 2018 [37]       | Systematic review and meta-analysis | 19 679 total patients | NA | NA | NA | All patients with rheumatic disease | HCl or CQ receipt was |
with systemic lupus erythematosus receiving high doses of HCQ for at least 318 days. Shapiro and Levy [32] in 2017 found decreased mortality with HCQ. In 514 RA patients (241 patients receiving HCQ and 273 controls), the mortality rate for HCQ was 22.4%, versus 38.5% in the control arm. A total of 13.3% of HCQ patients receiving 400 mg per day experienced cardiovascular events compared to 38.1% in the control group. The authors concluded that HCQ receipt in RA patients was associated with decreased cardiovascular morbidity, especially in higher-dosage HCQ, at 400 mg per day.

Neonatal cardiac lupus
Izmirly et al. [21] in 2012 showed the recurrence rate of cardiac neonatal lupus in foetuses exposed to HCQ was 7.5% (3/40) compared to 21.2% (46/217) in the unexposed group (p 0.050). While there were no deaths in the exposed group, the overall case fatality rate of the cardiac neonatal lupus foetuses in the unexposed group was 22%.

Atrial fibrillation
Gupta et al. [33] in 2018 showed a 67% decreased risk of atrial fibrillation in patients receiving HCQ.

Thrombosis
Three articles reported a decreased incidence of thrombosis in patients who received HCQ [20,24,25]. Konig et al. [24], in a 2019 presentation, found a lower incidence of thrombosis with a higher level of HCQ in the blood.

Cholesterol and lipid profile
Two articles showed lower cholesterol or lipid profile in patients receiving HCQ [22,26].

Clinical series providing HCQ in COVID-19
A clinical series of 1061 COVID-19 patients treated with HCQ and azithromycin reported eight deaths [2]. However, all of these deaths were caused by respiratory failure from COVID-19; no patients showed TDP. The authors obtained a baseline EKG in all patients and discontinued HCQ when necessary. They have now treated over 4000 patients with no cardiac mortality.

Azithromycin
We found five reports addressing the cardiotoxicity of HCQ in COVID-19 patients [27,28,34–36]. All articles described an increased risk of TDP or related ventricular arrhythmia. However, none of the five articles reported an actual death attributed to HCQ.

A report by Farkas [40] explained that HCQ is actually an antiarrhythmic drug and that it has never been shown to predispose its recipients to TDP. Ohara et al. [41] further described azithromycin as never having been shown to cause TDP. In addition, azithromycin has been shown to improve

---

**TABLE 1. Continued**

| Study            | Study type                   | No. of patients | HCQ dosage | HCQ duration | Associated medications | Comorbidities of patients and cardiac background | Study findings                                                                 |
|------------------|------------------------------|-----------------|-------------|--------------|------------------------|-----------------------------------------------|----------------------------------------------------------------------------------|
| Rampenault 2018  | Systematic review and meta-analysis | 12 245 patients receiving HCQ | NA          | NA           | NA                     | NA                                            | associated with 30% reduction in risk of CVD in patients with rheumatic disease Rheumatoid arthritis patients receiving HCQ showed modifiable risk factors for CVD, including improved lipid profile, diabetes incidence, HBA1C, and fewer cardiovascular events |
| Mathieu 2018     | Systematic review and meta-analysis | 24 923 patients receiving HCQ | NA          | NA           | NA                     | NA                                            | Rheumatic disease patients treated with HCQ had better CVD risk profile and fewer cardiovascular events |

AFib, atrial fibrillation; aPL, antiphospholipid antibody; CHF, congestive heart failure; COVID-19, coronavirus disease 2019; CQ, chloroquine; CVD, cardiovascular disease; DMARD, disease-modifying antirheumatic drug; ESRD, end-stage renal disease; HCQ, hydroxychloroquine; LDL, low-density lipoprotein; NA, not applicable; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SSA/Ro, anti-Sjögren syndrome–related antigen A, also called anti-Ro; SSB/La, anti-Sjögren syndrome–related antigen B, also called anti-La; TDP, torsades de pointes.
cardiac remodeling and decrease heart failure after myocardial infarction in animal models [42].

Discussion

The most important finding of this review is that evidence shows HCQ to be overall significantly cardioprotective and apparently not cardiotoxic in short-term receipt. This supports our hypothesis that prudent HCQ therapy would not cause significant mortality from TDP or related cardiac causes. This finding of cardioprotection, which was surprising to us, goes well beyond our hypothesis. Perhaps because many of the studies showing cardioprotection are relatively recent, the cardioprotective effect seems to be generally unknown to both the general population and the medical community. The cardioprotection includes a decrease in cardiac events, in thrombosis in general, in arrhythmia, in lipid profile and even in foetal disease. With HCQ generally beneficial to the heart in patients with rheumatic disease, there would be no reason to think that it would be cardiotoxic in COVID-19 patients, unless these patients were late in the disease course with established viral cardiac damage. Even then, this would be only a theoretical risk, because it is also possible that HCQ might be protective of further damage in this circumstance.

The second major finding of this study is that we were unable to find any reports of death due to HCQ-induced TDP in the peer-reviewed literature. This suggests that in fact no actual significant risk of TDP exists if HCQ is provided prudently and in accordance with established guidelines. In this regard, the protocol used by Raoult’s group is instructive [2]. They obtained a baseline EKG and serum electrolyte analysis before initiating HCQ. The EKG was repeated 48 hours after the start of treatment, and HCQ was discontinued when the corrected QT interval was >500 ms. Using this commonsense protocol, they have now treated over 4000 patients without a single cardiac mortality. TDP may occasionally occur in association with HCQ therapy. But on the basis of our finding of not a single death being reported in the peer-reviewed literature, we believe that the frequency of HCQ associated TDP is extremely low, and the incidence of subsequent TDP induced mortality caused by HCQ is rare, if it exists at all. Anecdotally, the Department of Health and Human Services’ pharmacovigilance memorandum [43], which publishes self-reported adverse events from providers and patients, reported four cases of TDP with one death in their entire database. This report is not peer reviewed. There is no way to verify the report itself, or causality or whether appropriate procedures were followed. However, at worst, this would still represent only a single TDP mortality despite widespread HCQ therapy for COVID-19.

The cardioprotective properties of HCQ should not be surprising. Cardiac events, including thrombosis, are caused in part by inflammation [44]. HCQ is an anti-inflammatory drug [45]. Furthermore, its separately described antithrombotic properties [46] would also be expected to be cardioprotective.

Limitations of this study include the possibility that cardiac deaths have occurred but not been reported. However, even if a small number of TDP deaths have occurred, it would not change the finding that HCQ is overall safe and generally beneficial for the heart.

In fact, the finding of an antithrombotic effect, an antiarrhythmic effect and a reduction in CVD events raises the possibility that HCQ should be considered in well-controlled clinical trials as a treatment for COVID-19 patients who have sustained cardiac damage as a possible mitigant of these effects.

Conclusions

HCQ is apparently not dangerous to the heart and indeed is cardioprotective. It results in a lower incidence of cardiac events as well as lower levels of arrhythmia, cholesterol and thrombosis. No TDP deaths from HCQ were reported in the peer-reviewed literature. The potential risk of fatal arrhythmia— for example, TDP—from HCQ appears to be merely theoretical. It appears to occur only rarely in clinical practice if HCQ is provided according to standard treatment protocols. Azithromycin provided in combination with HCQ also appears to be safe; it also does not appear to cause TDP mortality and is also apparently cardioprotective. As a result of its ability to decrease CVD events, decrease arrhythmia, decrease thrombosis and decrease cholesterol, HCQ should be considered as an agent for study to potentially treat patients who have developed cardiac damage from COVID-19.

Conflict of interest

None declared.

References

[1] Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, et al. [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. Zhejiang Da Xue Xue Bao Yi Xue Ban 2020;49:215–9.
[2] Million M, Lagier JC, Gautret P, Colson P, Fournier PE, Amranne S, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis 2020;35:101738.
[3] Yu B, Li C, Chen P, Zhou N, Wang L, Li J, et al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci. 2020.

[4] Olding R, Cartwright L. Controversial doc in Trump’s ear calls malaria drug study ‘garbage.’ Daily Beast. 22 May 2020. Available at: https://www.thedailybeast.com/vladimir-zelenko-controversial-doc-in-trumps-ear-calls-malaria-drug-study-garbage.

[5] Alia E, Grant-Kels JM. Does hydroxychloroquine combat COVID-19? A timeline of evidence. J Am Acad Dermatol 2020;83:633–4.

[6] Chowdhury MS, Rathod J, Gernsheimer J. A rapid systematic review of clinical trials utilizing chloroquine and hydroxychloroquine as a treatment for COVID-19. Acad Emerg Med 2020;27:493–504.

[7] Pastick KA, Okafa EC, Wang F, Lolgren SM, Skipper CP, Nicol MR, et al. Review: hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19). Open Forum Infect Dis 2020;7:ofaa130.

[8] US Food and Drug Administration (FDA). FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. Content current as of 1 July 2020. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting.

[9] US Centers for Disease Control and Prevention (CDC). CDC health alert network: severe illness associated with using non-pharmaceutical chloroquine phosphate to prevent and treat coronavirus disease 2019 (COVID-19). 28 March 2020. Available at: https://emergency.cdc.gov/han/2020/han00431.asp.

[10] Heart Failure Society of America (HFSA). Caution recommended on COVID-19 treatment with hydroxychloroquine and azithromycin for patients with cardiovascular disease. 8 April 2020. Available at: https://hfsa.org/caution-recommended-covid-19-treatment-hydroxychloroquine-and-azithromycin-patients-cardiovascular.

[11] US Food and Drug Administration (FDA). Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine. 15 June 2020. Available at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and.

[12] Fanouriakos A, Kostopoulos M, Alunu A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019;78:736–45.

[13] Sullivan L. Ohio pharmacy board restricts prescriptions for experimental coronavirus treatment drugs. Columbus (Ohio) Dispatch. 21 March 2020. updated 23 March 2020. Available at: https://www.dispatch.com/news/20200321/ohio-pharmacy-board-restricts-prescriptions-for-experimental-coronavirus-treatment-drugs.

[14] Azimian M, Gultekin SH, Hata JL, Atkinson JB, Ely KA, Fuchs HA, et al. Fatal antimalarial-induced cardiomyopathy: report of 2 cases. J Clin Rheumatol 2012;18:363–6.

[15] Nord JE, Shah PK, Rinaldi RZ, Weismann MH. Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. Semin Arthritis Rheum 2004;33:336–51.

[16] Morgan ND, Patel SV, Dworokina O. Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus. J Clin Rheumatol 2013;19:286–8.

[17] O’Laughlin JP, Mehta PH, Wang BC. Life threatening severe QTc prolongation in patient with systemic lupus erythematosus due to hydroxychloroquine. Case Rep Cardiol 2016;2016:4626729.

[18] Chen CY, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Philad) 2006;44:173–5.

[19] Ash R, Abdullah M, Chong P, Metussin D, Momin R, Mani B, et al. Case report: right bundle branch block and QTc prolongation in a patient with novel coronavirus disease (COVID-19) treated with hydroxychloroquine. Am J Trop Med Hyg 2020;103:79–82.

[20] Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002;41:924–9.

[21] Izmiry P, Mendoza-Chalumeau N, Pisoni CN, Khamashta MA, Kim MY, Saxena Am, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SS-A/Ro-antibody–associated cardiac manifestations of neonatal lupus. Circulation 2012;126:76–82.

[22] Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994;96:254–9.

[23] Hung YM, Wang YH, Lin L, Wang YP, Chiu SY, Wei JC. Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: a nationwide population-based cohort study. Int J Clin Pract 2018;72:e13095.

[24] Konig M, Li J, Petri M. Hydroxychloroquine blood levels and risk of thrombotic events in systemic lupus erythematosus. In: Paper presented at: 2019 American college of Rheumatology (ACR)/Association of Rheumatology professionals (ARP) annual meeting; 8–13 November 2019: Atlanta, GA. Abstract 2783; 2019.

[25] Ruiz-Irastorza G, Egurbide MV, Pijuan JI, Garmendia M, Villar I, Martinez-Berriotxoa A, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006;15:577–83.

[26] Rho YH, Oser A, Chung CP, Milne GL, Steen CM. Drugs used in the treatment of rheumatoid arthritis: relationship between current use and cardiovascular risk factors. Arch Drug Inf 2009;2:34–40.

[27] Bun SS, Taghji P, Courjon J, Squara F, Scarcisti D, Theodore G, et al. QT interval prolongation under hydroxychloroquine/azithromycin association for inpatients with SARS-CoV-2 lower respiratory tract infection. Clin Pharmacol Ther 2020.

[28] Saleh M, Gabriels J, Chang D, Kim BS, Mansoor A, Mahmood E, et al. The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection. Circ Arrhythm Electrophysiol 2020;13:e008662.

[29] Van Halm VP, Nurrohmid MT, Twisk JW, Dijkman BA, Voskuyl AE. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular complications in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006;8:R151.

[30] Sharma TS, Wasko MC, Tang X, Vedamurthy D, Yan X, Cote J, et al. Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. J Am Heart Assoc 2016;5:e002867.

[31] Yang DH, Leong PY, Sia SK, Wang YH, Wei JC. Long-term hydroxychloroquine therapy and risk of coronary artery disease in patients with systemic lupus erythematosus. J Clin Med 2019;8:796.

[32] Shapiro M, Levy Y. The association between hydroxychloroquine treatment and cardiovascular morbidity among rheumatoid arthritis patients. Oncotarget 2017;9:16155–22.

[33] Gupta A, Joshi A, Chester-Wasko M, Sharma TS. Association of hydroxychloroquine use and incident atrial fibrillation in systemic lupus erythematosus: a retrospective study. In: Paper presented at: 2018 American College of Rheumatology (ACR)/Association of Rheumatology Professionals (ARP) annual meeting; 19–24 October 2018: Chicago, IL. Abstract 2670; 2018.

[34] Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin. JAMA Cardiol 2020.
[35] Hooks M, Bart B, Vardeny O, Westmano A, Adabag S. Effects of hydroxychloroquine treatment on QT interval. Heart Rhythm 2020.

[36] Chorin E, Wadhwan L, Magnani S, Dai M, Shulman E, Nadeau-Routhier C, et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm 2020.

[37] Liu D, Li X, Zhang Y, Kwong JS, Li L, Zhang Y, et al. Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. Drug Des Devel Ther 2018;12:1685–95.

[38] Rempenault C, Combe B, Barnetche T, Gaujoux-Viala C, Lukas C, Morel J, et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2018;77:98–103.

[39] Matthei S, Pereira B, Tournadre A, Soubrier M. Cardiovascular effects of hydroxychloroquine: a systematic review and meta-analysis. Ann Rheum Dis 2018;77:e65.

[40] Farkas J. Myth-busting: azithromycin does not cause torsade de pointes or increase mortality. PulmCrit (EMCrit). 27 July 2015. Available at: https://emcrit.org/pulmcrit/myth-busting-azithromycin-does-not-cause-torsade-de-pointes-or-increase-mortality/.

[41] Ohara H, Nakamura Y, Watanabe Y, Cao X, Yamazaki Y, Izumi-Nakaseko H, et al. Azithromycin can prolong QT interval and suppress ventricular contraction, but will not induce torsade de pointes. Cardiovasc Toxicol 2015;15:232–40.

[42] Al-Darraji A, Haydar D, Chelvarajan L, Tripadi H, Levitan B, Gao E, et al. Azithromycin therapy reduces cardiac inflammation and mitigates adverse cardiac remodeling after myocardial infarction: potential therapeutic targets in ischemic heart disease. PLoS One 2018;13:e0200474.

[43] Swank K, McCartan K. Pharmacovigilance memorandum—review of hydroxychloroquine—chloroquine. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/OSE%20Review_Hydroxychloroquine-Chloroquine%20-%20May2020_Redacted.pdf.

[44] Esmon C. Inflammation and thrombosis. J Thromb Haemost 2003;1:1343–8.

[45] Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020;16:155–66.

[46] Belizna C. Hydroxychloroquine as an antithrombotic in anti-phospholipid syndrome. Autoimmun Rev 2015;14:358–62.